University biotech spinout company, Trogenix, has secured £70 million in new financing to expand, upscale and develop. On a mission to deliver breakthrough treatments and pursue cures for thousands of patients and families facing devastating diagnoses each year, spinout company, Trogenix, has secured £70 million in new financing to expand, upscale and develop. Pre-clinical studies have shown the biotech company's breakthrough Odysseus® platform can kill cancerous brain cells and stimulate the immune system, whilst leaving surrounding healthy cells and tissue untouched. This massive investment will accelerate Trogenix's lead programme in glioblastoma multiforme including the move to clinical trials. Hear Dr Faye Robertson from the Edinburgh Cancer Centre discuss this on Radio 5 Live. The story also featured in The Herald.Congratulations Steve Pollard (IRR) and colleagues! Publication date 21 Oct, 2025
